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ABSTRACT 
 
 
 
Pompe disease, a storage disease caused by a lack of lysosomal acid alpha-
glucosidase (GAA), results in systemic lysosomal glycogen accumulation and respiratory 
and muscle destruction. We propose that viral gene therapy can lower glycogen 
accumulation and relieve symptoms in a GAA-/- mouse model.  Two viruses were 
engineered to contain plasmids encoding GAA (AAVB1-GAA or AAV9-GAA), and 
were injected IV into 90-day old GAA-/- or WT mice.  Preliminary data with respiratory, 
behavioral, and histological assays suggest that both vectors improve the survival and 
pathology. 
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BACKGROUND 
 
Lysosomal Diseases 
 Lysosomal storage disorders (LSDs) are a group of rare genetic diseases caused 
by a lack of proteins involved in lysosomal pathways. They result in the accumulation of 
substances within the lysosomes. As lysosomes exist in all cells except for red blood 
cells, diseases that affect the lysosomes present with symptoms involving many body 
systems (Bruni et al., 2007). Many LSDs present with similar features, including 
organomegaly, skeletal abnormalities, central nervous system dysfunction, coarse hair, 
hepatosplenomegaly, facies, and varying levels of mental retardation (Meikle et al., 1999; 
Bruni et al., 2007). LSDs are grouped into different categories by the type of substrate 
that accumulates in the lysosome. These groups include PMSs, lipidoses, glycogenoses, 
and oligosaccharidoses.  
 LSDs share many characteristics, from their method of inheritance, to the range in 
severity of symptoms. Most LSDs are inherited in an autosomal recessive pattern; the 
three exceptions are Danon disease, Fabry disease, and Mucopolyccharidosis, each of 
which are X-linked recessive (Meikle et al., 1999). Almost all of these diseases have a 
broad range of both clinical severity and the range at which symptoms present. Even the 
same mutations in the same gene will not always cause disease presentation in the same 
manner or at the same age (Meikle et al, 1999). Due to the many differences in disease 
presentation between different individuals with the same genotype, it is likely that 
environmental and other genetic background have roles in the progression of LSDs 
(Meikle et al., 1999). 
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 There are at least 41 different LSDs, and they have a broad distribution of 
prevalence. A study analyzing data from Australia from 1980 through 1996 determined a 
combined occurrence of 1 child with an LSD in 7,700 live births, ranging from 1 in 
57,000 with Gaucher Disease, to 1 in 4.2 million with sialidosis (Meikle et al., 1999). 
 There are a variety of treatments for LSDs, with different levels of efficacy. Bone 
Marrow Transplantation (BMT) replaces the deficient enzyme activity with IV infusion 
of normal hematopoietic progenitor cells.  Since transplants require a donor with specific 
requirements, this therapy is only available to those able to find a suitable donor. BMT is 
only effective when performed before the diseased individual is three years old (Bruni et 
al., 2007). Another available treatment is Enzyme Replacement Therapy (ERT) which 
involves IV injection of the deficient enzyme. However, ERT does not cross the blood-
brain barrier so is unable to treat symptoms of LSDs involving the central nervous system 
(Bruni et al., 2007). In addition, Substrate Reduction Therapy slows the formation of the 
lysosomal substrate so that the residual enzyme is able to degrade the substrate without 
buildup in the lysosome. This therapy only works in instances where the enzyme is still 
present, and does not treat individuals with complete enzyme deficiency (Bruni et al., 
2007). Chemical Chaperone Therapy works to stabilize the enzyme by aiding in the 
stabilization and function of misfolded enzymes. This stabilization increases enzyme 
activity and thus decreases the accumulation of substrate in the lysosomes. Since this 
treatment works by fixing an existing enzyme, it only works for genotypes that produce 
the enzyme in question. Gene Therapy treats disease by inserting the normal gene into 
cells, therefore allowing the normally defective enzyme to be produced (Bruni et al., 
2007). 
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Acid Alpha-Glucosidase 
 Acid alpha-glucosidase (GAA) is a lysosomal enzyme that degrades the glycogen 
within lysosomes into glucose which then exits the lysosome. Specifically, GAA 
functions in the acidic environment of lysosomes to degrade alpha 1-4 and alpha 1-6 
glycosidic linkages in glycogen, maltose, and isomaltose (Brown and Brown, 1970; 
Muller-Felbert et al., 2007). Discovered in 1961 by H. G. Hers, GAA was found to be the 
cause of the LSD Pompe Disease (Hers et al., 1963).  
 Located on chromosome 17q23, the structural gene that encodes GAA is 28 kb in 
length, and includes 20 exons (Nickel et al., 1982; Martiniuk et al., 1991). The cDNA is 
3.6 kb with a 2,856 bp coding sequence that has a 5’ UTR of 218 bp and a 3’ UTR of 555 
bp (Mariniuk et al., 1986; Hoefsloot et al., 1988). The polypeptide produced is 952 amino 
acids, and has a predicted molar mass of 105 kDa (Hasilik and Neufeld, 1980). It is 
processed along a similar pathway as other lysosomal enzymes; the polypeptide is co-
translationally glycosylated in the endoplasmic reticulum (ER), its mannose residues are 
phosphorylated, and it is further processed in the ER and Golgi to different species, 
predominantly fragments of 76 and 70 kDa (Hasilik and Neufeld, 1980; Kornfeld, 1986). 
Pompe Disease 
 Pompe Disease, also called Glycogenosis Type II, Glycogen Storage Disease 
Type II, and Acid Maltose Deficiency, is a LSD caused by a deficiency of acid alpha-
glucosidase (GAA). Categorized by JC Pompe in 1932, it was the first LSD to be 
discovered (Kishnani et al., 2006). Pompe Disease is an autosomal recessive inherited 
disorder with progressively worsening symptoms from the onset of the disease. The 
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deficiency of GAA leads to an accumulation of glycogen within the lysosomes, 
especially in cardiac tissue, skeletal muscle, and smooth muscle (Winkel et al., 2004). 
This accumulation results in cellular dysfunction, structural disorganization, and 
abnormal autophagy (Fukuda et al., 2006). Pompe is extremely rare, with prevalence 
ranging from 1 in 33,000, to 1 in 300,000, with a combined incidence of 1 in 40,000 
(Kishnani et al., 2006). The occurrence depends on both geographic region and ethnicity 
(Martinuik et al., 1998; Ausems et al., 1999; Chien et al., 2008). There are two types of 
Pompe Disease, the quickly fatal infantile onset, and slowly progressive late onset 
(Martiniuk et al., 1991). Infantile onset Pompe Disease is more common in African-
Americans and Chinese populations, and Late Onset Pompe Disease (LOPD) has a higher 
incidence in The Netherlands (Kishnani et al., 2006). 
 Pompe disease results from a large variety of allelic mutations. Different 
mutations cause different levels of GAA mRNA or enzyme activity. A study (Martiniuk 
et al., 1998) found five out of 10 infantile onset patients with a complete lack of mRNA 
for GAA, and two out of 4 LOPD patients with mRNA of abnormal size. Another study 
found two thirds of infantile onset patients lacked any detectable mRNA (van der Ploeg 
et al., 2010). Other patients who still produce GAA have normal GAA activity without 
any abnormalities in the structure or function of the enzyme. These patients have reduced 
enzyme activity, but the enzyme activity that is present is normal (Reuser et al., 1978; 
Schram et al., 1979). The reduced levels of GAA activity most often occur because of 
defects in the synthesis or processing of the enzyme, and not from an increase in 
degradation of mature GAA (Reuser and Kroos, 1982). However, one study found 2 
patients whose GAA deficiency resulted from rapid degradation of either the precursor to 
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GAA or GAA itself (Steckel et al., 1982). There does not appear to be any correlation 
between the genotype causing the disease and the resulting phenotype (Muller-Felbert et 
al., 2007). 
 Infantile onset Pompe Disease occurs when symptoms start within the first year of 
life. The average onset of clinical symptoms in these individuals occurs at three months 
old, and untreated patients die between six months and 18 months (Bijvoet et al., 1998). 
Deaths are most often caused by either cardiac failure or respiratory failure (Muller-
Felber et al., 2007). Symptoms include cardiomegaly, severe generalized muscle 
weakness, and respiratory dysfunction, with most patients requiring invasive ventilation 
(Muller-Felbert et al., 2007; Wang et al., 2007). 
 LOPD occurs when the symptoms begin after the first year of life. There is large 
variability in the progression and clinical symptoms of this disease; the age of disease 
onset does not correlate with the severity of progression (Muller-Felbert et al., 2007). 
Symptoms affect almost all body systems, with large amounts of cardiac, muscular, and 
respiratory involvement. The most frequent presenting sign is progressive limb-girdle 
weakness (Muller-Felbert et al., 2007). A large number of LOPD patients become 
wheelchair bound (Winkel et al., 2005). The probability of an untreated individual with 
LOPD needing a wheelchair increases by thirteen percent every year after the diagnosis 
(Hagemans et al., 2005). In patients whose symptoms presented during childhood, 
deformities and delays in motor development often occur (Barba-Romero et al., 2012). 
Respiratory dysfunction develops in more than 70% of LOPD patients. Vital capacity is 
reduced by an average of 1.5% every year after diagnosis (Vand der Beek et al., 2009). A 
large number of individuals with LOPD require assisted ventilation; the likelihood of 
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needing invasive or non-invasive ventilation increases by eight percent every year after 
diagnosis (Hagemans et al., 2005). Cardiac glycogen accumulation affects the ability of 
the heart to function properly. Some LOPD individuals have Wolff-Parkinson-White 
syndrome, spontaneous activity, or myopathic EMG patterns. Others show no cardiac 
symptoms (Muller-Felbert et al., 2007). There are a variety of other symptoms that can 
occur in LOPD. 
 The current treatment for Pompe Disease is Enzyme Replacement Therapy 
(ERT). Approved in both the United States and Europe, ERT involves injections of 
recombinant human GAA from rabbit milk (Van den Hout et al., 2000; Toscano and 
Schoser, 2013). This treatment is recommended every two weeks for the rest of the 
patient’s life. Due to the amount of times treatment is needed and its high cost, ERT can 
cost a patient in the United States up to $300,000 each year for the rest of their life 
(Brady, 2006). 
In infants, ERT leads to increased survival and improvements in both skeletal and 
cardiac muscle (Klinge et al., 2005). It also delays the age at which assisted ventilation 
becomes necessary and markedly improves cardiac symptoms (Kishnani et al., 2009; 
Nicolino et al., 2009). Many patients are able to reach developmental and functional 
milestones such as walking and running that were never before possible (Kishnani et al., 
2009; Spiridigliozzi, 2012). Patients with a complete lack of GAA activity may develop 
antibodies against ERT, with one study finding 20% of infantile onset patients 
developing these antibodies (Amalfitano et al., 2001). Additional therapies of 
immunomodulation allow these GAA immune responses to be eliminated and those 
patients to effectively be treated with ERT (Messinger et al., 2012). However, infantile 
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onset patients treated with long-term ERT do not live normal lives. They present with 
dysphagia and other speech disorders, increased likelihood of skeletal fractures, muscle 
deterioration, and hearing loss (Kamphoven et al., 2004; Case et al., 2007; Case et al., 
2012; van Gelder et al., 2012). 
ERT stabilizes the progression of Pompe Disease in late onset patients but does 
not provide a cure. Twenty-one studies with a total of 368 LOPD patients found that 
about one half of the patients were stabilized or had improved muscular and/or 
respiratory function after starting ERT (Toscano and Schoser, 2013). Of the 115 patients 
with impaired ambulatory status at the start of ERT, 6.1% improved with ERT. Of these, 
one was able to use a wheelchair after being bedridden, three were able to walk short 
distances after previously only being mobile in a wheelchair, one wheelchair patient 
became able to walking with assistance, and the last was able to walk without assistance 
after needing a wheelchair before treatment (Toscano and Schoser, 2013). Seven studies 
with 122 patients found that 77.9% improved, 8.2% stabilized, and 13.9% declined in the 
six minute walk test, another measure of muscular performance (Toscano and Schoser, 
2013). Respiratory function was tested using forced volume vital capacity (FVC) and by 
tracking any assisted ventilation used. For 124 LOPD individuals on ERT, FVC 
improved in 51.6%, declined in 34.7%, and stabilized in 13.7%. Of 66 patients on 
ventilatory support before starting treatment, 59.1% improved, 36.4% stabilized, and 
4.5% declined (Toscano and Schoser, 2013). There was no correlation between a longer 
duration of ERT and greater improvements in motor or respiratory function. This lack of 
correlation suggests that ERT does not improve the symptoms of LOPD but merely 
stabilizes the progression of the disease (Toscano and Schoser, 2013). 
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Gene Therapy 
 Gene therapy is the insertion of nucleic acids such as DNA into cells in order to 
replace missing or defective genes and correct genetic disorders. It is a fairly recent type 
of therapy, with the first human gene therapy trial being performed in 1989 (Rosenberg et 
al., 1990). The death of Jesse Gelsinger in 1999 due to a reaction to the adenovirus-based 
vector that was supposed to be treating him caused a backlash against this method of 
treatment (Marshall, 1999). Subsequent lack of confidence in the efficacy of gene therapy 
limited research and trials. In 2004, China approved the first gene therapy for commercial 
production (Pearson et al., 2004). As of April 18, 2017, gene therapy is not approved for 
use in the United States except in research (American Society of Gene and Cell Therapy, 
2017). 
 For this project, a mouse model for Pompe Disease was used. The mouse model is 
a homozygous knockout for GAA. This model produces tissues and cultured cells that are 
completely deficient in GAA (Bijvoet et al., 1998). It presents with lysosomal glycogen 
accumulation that progresses over the course of its lifetime. The progressive glycogen 
storage causes similar cellular pathology in the mice as in humans (Bijvoet et al., 1998). 
The mouse model presents with symptoms that represent both infantile onset and late 
onset Pompe Disease. Similar to humans with infantile onset Pompe Disease, the mice 
have virtually complete GAA deficiency without detectable mRNA synthesis, cardiac 
pathology, and glycogen accumulation in motor neurons (Bijvoet et al., 1998). However, 
clinical symptoms do not present before adulthood, and the mice survive much longer 
than humans with infantile onset Pompe Disease. Thus, this knockout mouse model is a 
good representative for both types of Pompe Disease (Bijvoet et al., 1998). 
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 This project uses adeno-associated virus (AAV) to deliver the GAA gene. AAV 
viruses were discovered in 1965 by two groups simultaneously, one was Bob Atchison 
and the other was composed of M. David Hoggan and Wallace Rowe (Hastie and 
Samulski, 2015). AAV replication only occurs when the infected cells also contain 
adenoviruses. Even when it replicates, AAV does not cause any known pathology in 
mammals (Flotte, 2013). This non-enveloped virus has linear ssDNA genome with a 
length of 4,680 base pairs with 145 bases of IRT (Vector BioLabs, 2016). It attaches to 
cells via heparin sulphate proteoglycans and its internalization is aided by co-receptors on 
the cell surface (Vector BioLabs, 2016). When used for gene therapy, AAV allows for 
long-term expression with high yields of more than 100,000 particles per cell of the 
inserted gene (Hastie and Samulski, 2015; Vector BioLabs, 2016). This persistence, 
combined with the ability to infect a large variety of tissues makes AAV a popular choice 
for gene therapy (Pacak et al., 2008).  
The specific AAV serotypes and promoter were chosen for this project with the 
target organs in mind. Target tissue in the mouse model was respiratory tissue, skeletal 
muscle, brain, and spinal cord. AAV9 is known to effectively transduce the central 
nervous system, heart, liver, lung, and skeletal muscle (Addgene, 2017). AAVB1, which 
was generated in 2016 by S. Choudhury, transduces the brain, muscle, beta cells, 
pulmonary alveoli, and retinal vasculature. AAVB1 has better transduction than AAV9 to 
the brain, spinal cord, muscle, pancreas, and lung (Choudhury, 2016). The Desmin 
promoter was chosen for its generic targets. This promoter works well for systemic 
transgene delivery, and specifically targets cardiac muscle, skeletal muscle, and neurons 
(Pacak et al., 2008). 
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Interests of the El Mallah Lab at UMMS 
 The El Mallah Lab is part of the Gene Therapy Center at UMASS Medical 
School, and investigates using gene therapy to characterize and treat genetic disorders 
that affect the respiratory system. Other than this project on Pompe Disease, the El 
Mallah lab also works on potential treatments for amyotrophic lateral sclerosis (ALS) and 
very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD). 
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PROJECT PURPOSE 
 
 This MQP was designed to assess the ability of two AAV viruses, AAV9 and 
AAVB1, to serve as potential vectors for delivering GAA to GAA-/- mice by measuring 
GAA levels in GAA-KO mice using IHC microscopy, and measuring functional recovery 
in GAA-/- mice by respiratory function, hang strength, and survival time.  
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METHODS 
 
 
Viral Design 
AAVB1 and AAV9 were obtained from Miguel Sena-Esteves, PhD, at the 
UMASS Gene Therapy Center. Plasmids encoding GAA under the control of a desmin 
promoter were designed and inserted into the AAV viruses at the University of Florida. 
 
Mice 
All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Massachusetts Medical School. B6;129-
GaaTm1Rabn/J mice were acquired from Jackson Laboratory (Bar Harbor, ME). 
Littermate male knockout GAA-/- and wild type GAA +/+ were used after genotyping 
with standard PCR methods to confirm genotype. The GAA-/- genotype was confirmed 
by 251 bp product, and the GAA+/+ genotype was indicated by a 131 bp product. 
 
Viral Infections 
Male knockout GAA-/- and wild type GAA+/+ mice were injected with either 
PBS, or 1x1012 vector genomes of AAV9-GAA or AAVB1-GAA through the tail vein at 
90 days of age. At the indicated time point, physiological tests were run on the mice. At 
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270 days of age, the additional respiratory tests were run on the mice and tissues were 
collected for histological studies. 
 
Grip Strength 
Four limb grip strength tests were performed at 90 days, 120 days, 180 days, and 
270 days of age to determine muscular function over time. The mice were individually 
placed on a grip strength meter and pulled back steadily by the tail to determine the 
amount of force that could be sustained with all four of the mouse’s limbs. This test was 
repeated using only the mouse’s front two limbs to determine the amount of force able to 
be sustained by the forelimbs.  
 
Hang Test 
Mice were individually placed on an inverted screen. The amount of time that the 
mice were able to hold themselves up for with a maximum of 120 seconds was 
determined over two attempts. This test was repeated at 90 days, 120 days, 180 days, and 
270 days of age to determine muscular function over time. 
 
Airway Responsiveness 
Barometric plethysmography using whole body plethysmography (WBP) was 
used to test the airway responsiveness of the mice to increased respiratory demand. The 
chamber was calibrated with a two second injection of 20 mL air into the main chamber. 
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The pressure differences between the WBP containing the mouse and a reference 
chamber were measured and used to determine Peak Inspiratory Flow (PIF), Peak 
Expiratory Flow (PEF), Tidal Volume (TV), Minute Volume (MV), and Frequency (F). 
These measurements were determined over a ten minute period of normoxia (21% 
oxygen, 0% carbon dioxide) and a ten minute period of hypercapnia (21% oxygen, 7% 
carbon dioxide). Responsiveness was determined by calculating the percent change from 
normoxia to hypercapnia. 
 A FlexiVentTM piston system (SCIREQ, Montreal, Canada) was used to determine 
bronchial airway responsiveness of the mice at 270 days of age. The mice were 
anesthetized with an intraperitoneal injection of a mixture of ketamine (90mg/kg, Animal 
Health International) and xylazine (4.5mg/kg, Propharma). They were then intubated and 
connected to the FlexiVentTM via the tracheal cannula. Mice were ventilated with room 
air at a frequency of 150 breaths/minute with a volume of 10 mL/kg. FlexiVent program 
was used to take measurements by analysis of pressure and volume signals. Baseline 
measurements were taken. Additional measurements were obtained after incremental 
doses (3.125, 6.25, 12.5, 25, 50, and 100 mg/mL) of aerosolized methacholine, receiving 
two deep lung inflations between each dose. Measurements included respiratory system 
resistance (Rrs), resistance of central airways (Rn), small airway and tissue resistance 
(G), respiratory system elastance (Ers), and small airway and tissue elastance (H) and 
were taken every 15 seconds with 12 measurements per dose of methacholine.  
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Immunohistochemistry of GAA 
 Levels of GAA enzyme present in various tissues were assayed by 
Immunohistochemistry (IHC). Sections of the medulla, cervical spine, and thoracic spine 
were embedded in OCT. 40 µm sections were cut. To determine presence of GAA, 
sections were stained using an antibody against GAA and visualized by staining with 
3,3’-Diaminobenzidine (DAB). 
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RESULTS 
 
Vector Design 
 The plasmid vector encoding GAA was designed by the University of Florida 
(Figure-1). A desmin promoter (blue, upper right in the diagram) was used to control 
expression of the GAA gene from the plasmid (red, lower right in the figure). The 
plasmid vector was placed into AAV9 and AAVB1 serotypes and recombined with the 
viral DNA genome to create AAV9-GAA and AAVB1-GAA at the University of Florida.  
 
 
 
Figure 1: Map of the Plasmid Vector Inserted Into AAV. Shown is the 
plasmid vector inserted into AAV9 and AAVB2. This vector was designed and 
inserted into the AAV viruses by the University of Florida.  The GAA gene is 
denoted in red (lower right), and the desmin promoter controlling GAA 
expression is shown as blue (upper right). 
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Survival 
 Male GAA+/+ and GAA-/- mice were injected with either PBS or 1x1012 vector 
genomes of AAV9-GAA or AAVB1-GAA at 90 days old. There were 10 GAA+/+ mice, 
11 GAA-/- Group E (blind virus-1), 11 GAA-/- Group F (blind virus-2), and 17 GAA-/- 
PBS mice. The mice were harvested at 180 days. The survival of the mice up to the 
harvest point was tracked and plotted on a Kaplan-Meier graph (Figure-2). An analysis 
was performed and concluded that the GAA-/- PBS group was statistically different 
(lower survival) from the three other groups (p value of <0.05), indicating that each viral 
treatment improved the survival of GAA-/- mice. 
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Figure-2: Mouse Survival Curves. Shown are the survival means of 4 treatment 
groups shown in the legend (N = 10-17).  Groups E and F represent blinded viral 
treatments.  The GAA-/- PBS group (red) is statistically different from all other 
groups (p value of <0.05). Group E, Group F, and GAA+/+ are not statistically 
different from each other. 
 
Musculoskeletal Function 
 An inverted hang test and two- and four-limb grip strength tests were performed 
on the mice at time of injection, and 30 days, 90 days, and 180 days post-injection (PI) to 
determine musculoskeletal function over time (Figure-3). Statistical significance was 
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determined using One-Way ANOVA and Multiple Comparisons Test with a p value of 
0.05. The GAA+/+ PBS group was statistically different (stronger performance) from all 
the GAA-/- groups in the inverted hang test at all time points, the two-limb grip for at all 
times except 120 days, and the four-limb grip at 90 days and 120 days. The three GAA-/- 
groups were not statistically different from each other at any time point of the inverted 
hang, two-limb grip test, or four-limb grip test, suggesting that neither viral treatment 
measurably improved musculoskeletal function.  
 
 
 
 
 
 
 
 
 
Figure-3: Assay of Musculoskeletal Function.  Panel-A: Inverted hang test 
performed at 90, 120, 180, and 270 days of age. Injection point was 90 days. 
Panel-B: Two-limb grip strength test conducted at 90, 120, 180, and 270 days. 
Panel-C: Four-limb grip strength test performed at 90, 120, 180, and 270 days. 
 
Respiratory Function and Airway Responsiveness 
 Respiratory function was determined at 120, 180, and 270 days using 
plethysmography, and airway responsiveness was determined at 270 days using 
FlexiVentTM. Plethysmography was used to calculate the percent change from normoxia 
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to hypercapnia of PIF, PEF, TV, MV, and F (Figure-4). The results indicated that none 
of the viral treatments significantly altered respiratory function or airway responsiveness. 
 
 
Figure-4: Plethysmography. Whole body plethysmography performed at 120, 
180, and 270 days old. Percent of normoxia was calculated for each 
measurement. An asterisk shows a measurement statistically different from the 
GAA-/- PBS group (p=0.05). A. Peak Inspiratory Flow (PIF). B. Peak Expiratory 
Flow (PEF). C. Tidal Volume (TV). D. Minute Volume (MV). E. Frequency (F). 
 
 
To test airway resistance and elastance, FlexiVentTM was used on the mice at 270 
days. Pressure volume (PV) loops were determined, then additional resistance and 
elastance of the respiratory system, central airway, and small airway and tissue were 
determined using increasing doses of nebulized methacholine (Figure-5). 
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Figure-5: Airway Responsiveness. FlexiVentTM was used to determine PV 
loops, airway resistance, and airway elastance with increasing doses of nebulized 
methacholine. A. PV Loops. B. Respiratory system resistance (Rrs). C. 
Resistance of central airways (Rn). D. Small airway and tissue resistance (G). E. 
Respiratory system elastance (Ers). F. Small airway and tissue elastance (H). 
 
 
 The multiple comparisons test was used (p = 0.05) to determine if differences 
between groups were statistically significant. The PV loops show no difference between 
any of the groups (Figure 5A). The GAA+/+ group was different from all three GAA-/- 
groups at all doses except 0, 1.5, and 50 mg/mL methacholine for Rrs, and none of the 
GAA-/- groups were different from each other (Figure 5B). For Rn, the groups were all 
the same except for at 100 mg/mL methacholine, at which the GAA+/+ group was 
significantly different (Figure 5C). Similarly, all the groups were the same for G except 
for the GAA+/+ group at 25 and 100 mg/mL methacholine (Figure 5D). The GAA+/+ 
group had a different Ers from the GAA-/- groups at 6.25, 12.5, and 15 mg/mL 
methacholine, and a different H at 50 and 100 mg/mL methacholin (Figures 5E and 5F). 
There was no significant difference between any of the GAA-/- groups for any of the 
airway resistance or elastance measurements. 
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GAA Presence in Central Nervous System 
 The presence or lack of GAA in the motor neurons was determined by immuno-
histochemical staining (IHC). IHC was performed on 40 μm sections of the medulla, 
cervical spine, and thoracic spine using an antibody against GAA and DAB to visualize. 
The sections were photographed under a microscope at 8X (Figure-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: IHC of GAA on Medulla, Cervical Spine, and Thoracic Spine 
Sections at 8X.  Shown are examples of motor neurons containing stained GAA.  
Black arrows denote positive areas of GAA staining.  A. GAA+/+ PBS medulla. 
B. GAA-/- Group E medulla. C. GAA -/- Group F medulla. D. GAA-/- PBS 
medulla. E. GAA+/+ PBS cervical spine. F. GAA-/- Group E cervical spine. G. 
GAA-/- Group F cervical spine. H. GAA-/- PBS cervical spine. I. GAA+/+ PBS 
thoracic spine. J. GAA-/- Group E thoracic spine. K. GAA-/-.  Group F thoracic 
spine. 
 
 All sections of GAA+/+ PBS medulla, cervical spine, and thoracic spine had a 
large number of motor neurons containing GAA (Figure 6A, Figure 6E, and Figure 6I). 
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No GAA-/- PBS sections contained any motor neurons that had GAA (Figure 6D and 
Figure 6H). Group E (viral-1 treated) sections showed no GAA-positive motor neurons in 
the medulla or cervical spine, and a small amount of GAA-positive motor neurons in the 
thoracic spine (Figure 6B, Figure 6F, and Figure 6J). Group F (viral-2 treated) contained 
motor neurons with GAA staining in all three areas. There were fewer GAA-containing 
motor neurons in the medulla and cervical spine than in the thoracic spine (Figure 6C, 
Figure 6G, and Figure 6K). For all spinal sections, the GAA+/+ PBS group had the 
greatest amount of motor neurons containing GAA. 
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DISCUSSION 
 
Both AAV9-GAA and AAVB1-GAA increased survival in GAA-/- mice. Neither 
group measurably improved musculoskeletal or respiratory function. Since the increase in 
survival was not due to improvements in either the musculoskeletal or respiratory 
systems’ functions, this project was unable to determine the cause of increased survival. 
Both AAV9-GAA and AAVB1-GAA successfully delivered the GAA gene to the central 
nervous system, as AAV9-GAA induced GAA expression in motor neurons of the 
thoracic spine, and AAVB1-GAA caused GAA expression in motor neurons of the 
medulla, cervical spine, and thoracic spine.  
The sample sizes for all four groups were fairly small. The GAA+/+ PBS group 
had 10, the GAA-/- AAV9-GAA and GAA-/- AAVB1-GAA both had 11, and the GAA-
/- PBS groups had 17. These small sample sizes could have skewed the results, especially 
for the respiratory function tests which had large amounts of variance. 
The GAA-/- PBS mice that died before they reached end-point were not autopsied 
to determine cause of death. Knowing the cause of death could have led to insights of 
how AAV9-GAA and AAVB1-GAA increased survival.  
The next steps for this project include determining GAA expression and glycogen 
accumulation for more tissues to determine where the two AAV vectors were able to 
induce GAA expression and thus lessen glycogen accumulation. It would be interesting if 
both vectors successfully induced GAA expression in the skeletal muscles and respiratory 
tissue but did not improve musculoskeletal or respiratory function. 
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For the future, it would be interesting to test a combined therapy of ERT and gene 
therapy, since ERT has been shown to stabilize musculoskeletal and respiratory function. 
By combining ERT with gene therapy, the glycogen accumulation in the CNS would be 
lessened and musculoskeletal and respiratory functions might be stabilized. This 
combined treatment would hopefully perform better than ERT alone. 
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